Sponsors

Genomic test for tumour grade

Ipsogen, a company that markets molecular diagnostics assays for leukaemia, has launched MapQuant DxT Genomic Grade. The new assay is a molecular diagnostic test for breast tumour grade, which is an indicator of tumour proliferation, metastasis risk and response to chemotherapy.

Histological tumour grading is considered to be a decision factor in most national and international guidelines on breast cancer treatment. While it is generally recommended that high-grade breast cancer be treated with chemotherapy because it is chemosensitive, most low-grade breast tumours have a good prognosis and often do not respond to chemotherapy.

www.ipsogen.com

Latest Issues

RSM / Path Soc 2026 Winter Meeting

The Royal Society of Medicine, 1 Wimpole St, London, W1G 0AE
20 - 21 January, 2026

BIVDA Regulatory Affairs Seminar

Grand Hotel, Birmingham
10 - 11 February, 2026

BDIAP Molecular Pathology Study Day

10 Union Street, London, SE1 1SZ
2 March, 2026

USCAP 115th Annual Meeting

Henry B. González Convention Center, San Antonio, Texas, USA
21 - 26 March, 2026